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Background: The outcome of incisional and ventral hernia repair depends on surgical technique, patient,
and material. Permacol surgical implant (crosslinked porcine collagen) has been used for over a
decade; however, there are few data on outcomes. This study is the largest retrospective multinational
study to date to evaluate outcomes with Permacol surgical implant in the repair of incisional and
ventral hernias.
Methods: Data were collected retrospectively on 343 patients treated for 213 incisional and 130 ventral
hernias. Data evaluated included patient demographics, wound classiﬁcation, surgical technique,
morbidity, and recurrence rates.
Results: Median follow-up time was 649 days (max: 2857), median age 57 years (range 23e91), and BMI
32 kg/m2 (range 17.6e77.8). Two or more comorbidities were present in 70% of patients. Open surgery
was performed in 220 (64%) patients. Permacol surgical implant was used as an underlay (250), sublay
(39), onlay (37), or inlay (17). Surgical techniques included component separation (89; 25.9%), modiﬁed
Stoppa technique (197; 57.4%), and RiveseStoppa (17; 5.0%). CDC Surgical Wound Classiﬁcation was Class
I (190), Class II (103), Class III (28), and Class IV (22). Complications were seen in 40.5% (139) of the
patients, with seroma (19%) and wound infection (15%) as the most common. Mesh removal occurred in 1
(0.3%) patient. KaplaneMeier analysis demonstrated that the probabilities for hernia recurrence at one,
two, and three years were 5.8%, 16.6%, and 31.0%, respectively.
Conclusions: Permacol surgical implant was shown to be safe with relatively low rates of hernia
recurrence.
Clinical trial registration number: NCT01214252 (http://www.clinicaltrials.gov).
 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Invasive Surgery, Loyola Uni-
60 South First Avenue, Bldg.
e, PA, USA.
ciates Ltd. Published by Elsevier Lt1. Introduction
The repair of incisional and ventral hernias is one of the most
common general surgical procedures. Trends of an aging and obese
population should translate into an even larger demand for these
procedures in the future [1,2]. While the recommended treatment
for ventral and incisional hernias is surgery, either for symptom
relief or complication prevention, primary suture repair hasd. All rights reserved.
B. Chand et al. / International Journal of Surgery 12 (2014) 296e303 297
ORIGINAL RESEARCHdemonstrated high rates of failure ranging from 49% to 63% [3e5].
The incorporation of synthetic mesh into the repair has reduced
recurrence rates to between 10% and 30%, although this beneﬁt is
tempered by a potential increased risk of infectious complications
secondary to synthetic prosthetic insertion [5e7]. There are many
considerations that must be taken into account when choosing the
type of prosthetic for abdominal wall defect repair. The technique
and positioning of the mesh, systemic and local patient factors, and
the type of product all affect recurrence rates [8]. A recent literature
review recommends that collagen-based repair material be used in
patients considered at increased risk for surgical site occurrences as
an alternative to standard synthetic mesh [8], based on the risk of
potential subsequent mesh contamination or infection.
Surgeons may consider the use of collagen-based materials in
place of permanent synthetic mesh based on the presumption that
collagen-based materials may facilitate management of infection
without necessitating removal of repair material. As collagen-based
meshes support tissue incorporation and revascularization [9], they
may also facilitate the clearance of bacterial contamination [10].
Therefore, collagen-based meshes are an attractive alternative,
with increasing literature supporting their role in reducing the risk
of persistent infectious complications [11].
The primary aim of this study was to evaluate outcomes with
Permacol surgical implant in ventral and incisional hernia repair
in a real world setting to gain a better understanding of its clinical
safety and effectiveness in all wound classes. The incidence of
perioperative complications, including wound infection, seroma
formation, wound dehiscence, and ﬁstula formation, was evalu-
ated. Hernia recurrence was clinically assessed in all patients for at
least one year post-operatively. Subgroup analyses were performed
to analyze risk factors for recurrence.2. Methods
2.1. Study design
This study was a multinational multicenter retrospective anal-
ysis of the use and outcomes of Permacol surgical implant during
and after repair of abdominal wall defects and incisional and
ventral hernias (including umbilical hernias). Permacol surgical
implant (Covidien, Mansﬁeld MA, USA) is a porcine-derived acel-
lular dermal sheet predominantly composed of Type I collagen. The
proprietary manufacturing process removes cellular material, and
the remaining collagen is treated with hexamethylene diisocyanate
(HMDI) to supplement natural crosslinks. All patients received
Permacol surgical implant, but there was no standardization of
technique, method of implantation or ﬁxation, or consideration of
patient selection. The overall intent of the study was to evaluate
clinical outcomes of Permacol surgical implant based on surgeon
preference in select high-usage institutions across the US and
Europe. Study site selection was based on surgeon and center
experience and familiarity with the use of the implant. A total of 12
centers obtained IRB/EC approval. While the study did not have
onsite monitoring, data were entered into a central electronic
database that was reviewed systematically for data inconsistencies
and discrepancies. Any queries were issued to sites for resolution.
Subject eligibility included 18 years of age, having undergone
surgical hernia repair or reconstruction of abdominal wall defects
with Permacol surgical implant, and having a minimum of 12
months (30 days) post-surgery follow-up. Patients who had un-
dergone inguinal, parastomal, diaphragmatic, or paraesophageal/
hiatal hernia repair or who had prior implantation of Permacol
surgical implant during abdominal wall or hernia repair were
excluded.2.2. Data collection
Preoperative data collection included demographic information,
associated comorbidity risk factors, prior abdominal wall surgery
history, previous medical history, and a determination of prior
mesh, superﬁcial or deep, surgical site infections. Procedural data
collection included indication of surgery, surgical approach, dura-
tion of operation, American Society of Anesthesiologists (ASA)
classiﬁcation, size of mesh, implantation method, surgical tech-
nique, ﬁxation method, and wound classiﬁcation. Post-operative
data included types and management of complications and her-
nia recurrence deﬁned by clinical assessment. Medical record re-
view with documentation of abdominal exam fulﬁlled the criteria
of no hernia or hernia recurrence. Further conﬁrmatory imaging
was left to the discretion of the investigator. A telephone interview
was conducted for patients without a conﬁrmed diagnosis based on
medical record review or records not dated 12 (-30 days) months
post-surgery. If no recurrence was indicated by phone interview,
the patient was deemed to meet the criteria of no hernia or hernia
recurrence. If recurrence was indicated during the interview, pa-
tients were invited in for a clinical assessment to conﬁrm diagnosis.
Patientsmet the classiﬁcation of unconﬁrmed hernia if a recurrence
was diagnosed by telephone interview but not conﬁrmed by clin-
ical examination.2.3. Safety evaluation
The safety population included all 343 patients. In-hospital
complications and post-discharge complications were assessed,
and included wound infection, seroma, hematoma, pain, tearing/
ripping of the mesh, and ﬁstula. The relationship of the event to the
device, procedure, or underlying disease, as well as severity of the
event (mild, moderate, severe), were assigned by investigator ac-
cording to clinical judgment. In-hospital complications were
deﬁned as occurring on the day of surgical implant and prior to or
on the date of discharge. Post-discharge complications were
deﬁned as complications occurring after hospital discharge. Per
protocol, complications were recorded regardless of whether
intervention was required.2.4. Statistical analysis
This study was performed for data-gathering purposes with no
formal hypothesis testing. Statistical analysis was performed using
SAS Version 9.2 on the per-protocol population (excluding missing
data and taking into account all subjects with at least 12 months
follow-up data (-30 days)). Qualitative variables were described by
absolute and relative (%) frequency of each class or value. Quanti-
tative variables were described by mean, standard deviation, me-
dian, extreme values (minimum and maximum values), and
number of missing data points. In addition, a time-to-event analysis
(using KaplaneMeier estimates and Cox Regressions) was per-
formed to summarize the hernia recurrence data, including both
conﬁrmed and unconﬁrmed recurrences.
All datawere analyzed for each procedure separately. Additional
sub-group analyses were performed for conﬁrmed diagnoses
(based on medical chart review or follow-up visit), unconﬁrmed
diagnoses (based on Symptom Questionnaire only), and compli-
cations, stratiﬁed by procedure, surgery route, surgery technique,
and risk factors. Statistical tests were performed using a two-sided
signiﬁcance level of 5%. For qualitative variables, a Chi-square test
was performed, or a Fisher exact test was used if the assumptions of
the Chi-square (theoretical frequencies less than 5) were not met. P
values from the Chi-square test were presented for categorical
Table 1
Summary of demographic and baseline characteristics e per-protocol
analysis set.
Per protocol N ¼ 343
Region, N (%)
USA 234 (68.2)
Europe 109 (31.8)
Mean age (SD) 57.1 (14)
Median [minemax] 57 [23e91]
Gender, N (%)
Male 162 (47.2)
Female 181 (52.8)
Race, N (%)
White 326 (95)
Black 6 (1.7)
Other 11 (3.2)
Mean BMI (SD)a 33.7 (8.6)
Median [minemax] 32 [17.6e77.8]
Acronyms: body mass index (BMI), standard deviation (SD).
a 17 subjects with missing BMI.
Table 2
Summary of comorbidities e per-protocol analysis set.
Per protocol N ¼ 343
Diabetes 67 (19.5)
Obesity (BMI  30) 207 (60.3)
Corticosteroid treatment 16 (4.7)
Smoking 63 (18.4)
COPD 29 (8.5)
Heart disease 4 (1.2)
Hypertension 8 (2.3)
Treatment for recurrence 112 (32.7)
Age  60 153 (44.6)
History of cancer 77 (22.4)
Number of comorbidities
No comorbidity 25 (7.3)
1 comorbidity 78 (22.7)
2 or more comorbidities 240 (70.0)
At least 1 comorbidity 318 (92.7)
Acronyms: body mass index (BMI), chronic obstructive pulmonary disease
(COPD).
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values from the t test were presented for continuous efﬁcacy
endpoints.
To determine which factors may inﬂuence recurrence of hernia,
a multivariate Cox proportional hazards model was performed,
with recurrence within 12 months or 24 months as the dependent
variable. Comorbidities, wound classiﬁcation, gender, site, laparo-
scopic and open surgery, method of mesh placement, mesh size, in-
hospital complications, post-discharge complications, and infection
status prior to surgery were included in the model as independent
variables.
3. Results
After enrolling 425 patients (August 2010eOctober 2011), there
were 82 patients censored from the full analysis population. Thir-
teen patients did not meet all eligibility criteria and 69 patients did
not meet the 12-month follow-up minimum (Fig. 1), leaving 343
per-protocol patients.
The study population was 47% male and 95% Caucasian with a
median age of 57 years (range 23e91) (Table 1).
A summary of patient comorbidities that may impact post-
operative recovery and surgical outcomes is provided in Table 2.
Of the 343 patients, 240 (70.0%) had two or more comorbidities,
including 60.3% with a BMI  30 (obesity Class I or greater), 44.6%
over age 60, and 112 (32.7%) treated for recurrence. Table 3 de-
scribes the surgical procedures performed. The majority of the
operations were elective (91.8%) using an open approach (64.3%).
Incisional hernias were repaired in 213 patients (62.1%); the
remaining 37.9% of patients received abdominal wall defects/
ventral hernias repairs. 112 patients (32.7%) were being treated for
hernia recurrence. At the time of surgery, 33 patients (9.6%) had a
loss of domain, 30 patients (8.7%) had infected mesh removed, and
an additional 19 patients (5.5%) had active wound infections. Five
patients underwent a staged hernia repair. The median operative
time was 146 (range 18e540) minutes. The median length of hos-
pital stay was 6 (range 1e105) days.
3.1. Hernia recurrence
Among the 343 patients all have at least one year of follow-up,
139 (40.5%) have at least two years of follow-up and 72 (21.0%) have
at least three years of follow-up. Hernia recurrence rates were
determined by review of medical records in 238 patients (69.4%),
phone interview in 95 patients (27.7%), and per-protocol clinic
follow-up in 10 patients (2.9%). Overall, hernia recurrence wasFig. 1. Patients includeobserved in 20 (5.8%) conﬁrmed cases with a follow-up of 12
months (all conﬁrmed by medical chart review). There were no
unconﬁrmed hernias in the ﬁrst year. Twelve-month recurrence
rates were assessed by the subject’s relevant medical history or
comorbidities. There was no correlation between recurrence and
number of comorbidities or any speciﬁc type of comorbidity within
12 months, as conﬁrmed by multivariate Cox regression analysisd in the analysis.
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cancer had a signiﬁcant inﬂuence on recurrence within 24 months
(P ¼ 0.017 and 0.049), There were two unconﬁrmed hernias during
year two that were included in the regression analysis.
KaplaneMeier analysis (Fig. 2) demonstrated 5.8%, 16.6%, 31.0%
probabilities for hernia recurrence at one, two, and three years,
respectively. Based on this survival analysis there are 20 re-
currences the ﬁrst year (20/343; 5.8%), 26 recurrences the second
year (26/320; 8.1%) and 19 recurrences the third year (19/133;
14.3%) (Table 5). Unconﬁrmed hernia recurrences included in the
KaplaneMeier analysis include zero in year one, two during year
two, and ﬁve during year three. Patient wound classiﬁcation at the
time of surgery included 190 (55.4%) Class I, 103 (30%) Class II, 28
(8.2%) Class III and 22 (6.4%) Class IV. However, when using theTable 3
Description of surgical procedure e per-protocol analysis set.
Per protocol
Repair type, N (%) 343 (100)
AW defect/hernia repair 231 (67.3)
Hernia recurrence 112 (32.7)
Duration of surgerya (minutes)
N, mean (SD) median [minemax]
310, 154.3 (99.9) 146 [18e540]
Type of surgery, N (%) 343 (100)
Elective 315 (91.8)
Emergent 28 (8.2)
Surgical approachb, N (%) 342 (100)
Open 220 (64.3)
Laparoscopic 122 (35.7)
Indication for surgery, N (%) 343 (100)
AW defect 74 (21.6)
AW defect þ incisional hernia 9 (2.6)
AW defect þ ventral hernia 7 (2)
Incisional hernia 177 (51.6)
Incisional hernia þ ventral hernia 26 (7.6)
Ventral hernia 49 (14.3)
AW defect þ incisional hernia
þ ventral hernia
1 (0.3)
ASA classiﬁcationc, N (%) 342 (100)
Class I 27 (7.9)
Class II 209 (61.1)
Class III 100 (29.2)
Class IV 6 (1.8)
Loss of domaind, N (%) 342 (100)
Yes 33 (9.6)
Size of Permacol implant used (cm2)
N, mean (SD) median [minemax]
336, 295.4 (254.4) 250 [25e3168]
Implants by sizee, N (%) 336 (100)
<200 cm2 154 (45.8)
200e400 cm2 89 (26.5)
400 cm2 93 (27.7)
Implant placement method, N (%) 343 (100)
Inlay (no overlap) 17 (5)
Onlay (suprafascial) 37 (10.8)
Sublay (subfascial, extraperitoneal) 39 (11.4)
Underlay (subfascial, intraperitoneal) 250 (72.9)
CDC Wound classiﬁcation, N (%) 343 (100)
Class I e clean 190 (55.4)
Class II e clean-contaminated 103 (30)
Class III e contaminated 28 (8.2)
Class IV e dirty-infected 22 (6.4)
Infection status at surgery, N (%) 343 (100)
None 294 (85.7)
Infected mesh 30 (8.7)
Wound infection 19 (5.5)
Acronyms: American Society of Anesthesiologists (ASA), abdominal wall (AW),
Centers for Disease Control (CDC), standard deviation (SD).
a 33 subjects with missing values for duration of surgery.
b 1 subject with missing type of surgery (open/laparoscopic).
c 1 subject with missing ASA score.
d 1 subject with missing loss of domain.
e 7 subjects with missing mesh size.Ventral Hernia Working Group (VHWG) grading system [8],
approximately 90% of patients were categorized into Grade 2 (175)
or Grade 3 (131), as seen in Table 6. Comorbidities used were
consistent with those used in the ﬁnal analysis: age  60, obesity,
COPD, diabetes, smoking, corticosteroid, cancer history, recurrence,
hypertension, and heart disease. Based on this categorization,
overall hernia recurrence rates were similar across all VHWG
grades (P ¼ 0.427) (Table 6). A multivariate Cox proportional haz-
ards model conﬁrmed that wound classiﬁcation, wound infection,
and seromas were not predictors of hernia recurrence within 12 or
24 months (Table 7). However, sub-group analyses of patients with
recurrences at 12 months demonstrated signiﬁcant differences in
hernia recurrence rates by open versus laparoscopic procedure type
(7.7% versus 2.5%, P ¼ 0.047) and mesh location, with onlay
(suprafascial) repair at 18.9% recurrence and underlay (subfascial,
intraperitoneal) repair at 2.4% recurrence (P < 0.0001). Recurrence
rates by surgical technique ranged from 33.3%with the onlay repair
to 4.1% with the modiﬁed Stoppa (P¼ 0.038), as shown in Table 8. A
cumulative recurrence rate of 30.3% was experienced in the sub-
group of 33 patients with loss of domain at the time of operation,
with a recurrence rate of approximately 12% in each of years one
and two.3.2. Seromas and infectious complications
Cumulative (in-hospital þ post-discharge) complication rates
(Table 9) include wound infection 15.2% (52/343), seroma 19.0%
(65/343), hematoma 3.2% (11/343), and ﬁstula 0.9% (3/343). As
expected, when reviewing wound classiﬁcations, there was a cor-
relation between a history of infectious complications and devel-
opment of a post-operative infection (P < 0.0001) (Table 10).
Evaluation of potential cause of seroma formation is shown in
Table 11. Seromas occurred in 32% of laparoscopic procedures
compared to 11.8% of open procedures. Drains were not placed in
laparoscopic procedures andwere in 80% of open procedures. There
were no in-hospital complications related to the study device;
however, there were 3 (0.9%) severe post-discharge device-related
complications reported in three patients, including seroma, wound
dehiscence, and tearing of mesh. There was 1 (0.3%) incidence of
implant ossiﬁcation of moderate severity and unknown cause, and
2 (0.6%) incidences of a non-hernia bulge of moderate severity
possibly attributed to implant laxity. Re-operations requiring mesh
explantation occurred in only 1 (0.3%) patient, which was catego-
rized as procedure-related. There was no reported complication of
pain, and no 30-day mortality.Table 4
Multivariate Cox regression between hernia recurrences and comorbidities.
Comorbidities Recurrences within
12 months, P values, (20/343
subjects with recurrence)
Recurrences within
24 months, P values, (46/343
subjects with recurrence)
Diabetes 0.730 0.427
Obesity
(BMI  30)
0.732 0.614
COPD 0.455 0.760
Corticoids 0.913 0.330
Smoking 0.617 0.201
Heart disease 0.995 0.987
Hypertension 0.993 0.833
Age  60 0.246 0.211
History
of cancer
0.131 0.049
Recurrence 0.176 0.017
Acronyms: body mass index (BMI), chronic obstructive pulmonary disease (COPD).
Fig. 2. KaplaneMeier curve for hernia recurrences.
Table 6
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Collagen-based prosthetics for hernia and tissue repair have
existed for over a decade. Despite an initially enthusiastic adoption
by the surgical community, clinical data supporting product safety
and efﬁcacy and proper indication is needed. The use of biologics is
still controversial in Class III (contaminated) and IV (infected)
wounds and ﬁelds with increased collagenase due to potential
accelerated breakdown of the collagen-based materials in these
more hostile environments and limited evidence of long-term ef-
ﬁcacy under those conditions.
The collagen-based material evaluated in this large retrospec-
tive multi-center and multi-national clinical study was Permacol
surgical implant, a porcine-derived acellular dermal sheet with
chemical crosslinking to increase graft stability and durability. The
durability of this implant was demonstrated by a low hernia
recurrence rate independent of patient comorbidities (with the
exception of a history of previous hernia surgery inﬂuencing re-
currences within 24months), CDCwound classiﬁcation, and VHWG
Grade. In contrast, a study of 53 consecutive patients with ventral
hernia repair in a potentially contaminated setting reported an
overall recurrence rate of 17%, with a substantial inﬂuence of
wound class on risk of recurrence; recurrence rates in dirty andTable 5
Year of occurrence of the hernia recurrences (conﬁrmed and un-
conﬁrmed) at the repair site.
Per protocol, n/N (%)
First year 20/343 (5.8)
Second yeara 26/320 (8.1)
Third yearb 19/133 (14.3)
a Recurrence between 366 and 730 days among subjects with
follow-up >365 days (KaplaneMeier analysis).
b Recurrence between 731 and 1095 days among subjects with
follow-up >730 days (KaplaneMeier analysis).clean wounds were 39% and 5%, respectively, after one year [12]. In
our opinion, this disparity in wound occurrence may be due to the
non-crosslinked biologic (Surgisis Cook Medical, IN, USA)
breaking down too quickly in a contaminated ﬁeld. In comparison,
Permacol surgical implant had a one-year hernia recurrence rate
of 7.4% in clean wounds and 4.5% in dirty wounds.
Important biologic mesh properties include an intact extracel-
lular matrix and the ability to support tissue regeneration through
revascularization and cell repopulation [13]. The low hernia
recurrence rates and explant, ossiﬁcation, and non-hernia bulge
rates below 1% demonstrate the ability of the crosslinked
Permacol surgical implant to provide durability while still being
incorporated successfully. However, reported efﬁcacy rates vary
across crosslinked materials. Chavarriaga et al. [14] report on 18
patients who underwent abdominal wall reconstruction for com-
plex defects using CollaMend (Davol, RI, USA), an acellular porcine
dermal xenograft crosslinked with 1-ethyl-3-carbodiimide-hydro-
chloride (EDC). The wound class was Clean (44%), Clean-
contaminated (6%), Contaminated (33%), and Dirty (17%), with an
overall recurrence rate of 44%. Postoperative infection occurred inVentral hernia working group (VHWG) grade.
VHWG Grade # of patients # of recurrences
at 12 months
% Recurrence
at 12 months
Grade 1 15 0 0.00
Grade 2 175 14 8.00
Grade 3 131 5 3.82
Grade 4 22 1 4.55
Overall (P ¼ 0.427a) 343 20 5.83
Grade 1: Class I e clean; no comorbidity.
Grade 2: Class I e clean; at least 1 comorbidity.
Grade 3: Class II e clean-contaminated, or Class III e contaminated.
Grade 4: Class IV e dirty-infected.
a Overall hernia recurrence rates across all VHWG grades.
Table 7
Multivariate Cox regression analysis with wound classiﬁcation, wound infection,
and seromas as predictors of hernia recurrence.
Recurrences within
12 months, P values,
(20/343 subjects
with recurrence)
Recurrences within
24 months, P values,
(46/343 subjects
with recurrence)
Wound graduation
Class II 0.135 0.804
Class III 0.990 0.607
Class IV 0.621 0.532
Post-operative
seroma
0.323 0.291
Post-operative
wound infection
0.792 0.619
Fascia closure 0.002 0.058
Table 9
Post-operative complications e per-protocol analysis set.
N (%) Per protocol, N ¼ 343
Number of subjects with
post-operative complications
139 (40.5)
Seroma 65 (19)
Wound infection 52 (15.2)
Hematoma 11 (3.2)
Pulmonary/respiratory insufﬁciency 4 (1.2)
Fistula 3 (0.9)
Pneumonia 3 (0.9)
Tearing/ripping of mesh 3 (0.9)
Poor cosmesis/bulging, no hernia 2 (0.6)
Reaction to tegaderm/tape burn 2 (0.6)
Deep vein thrombosis 1 (0.3)
Ileus 1 (0.3)
Implant ossiﬁcation 1 (0.3)
Lysis of adhesions 1 (0.3)
Post-operative chest infection 1 (0.3)
Recurrence of hernia repair 1 (0.3)
Chest pain during course 1 (0.3)
Small bowel leak 1 (0.3)
Tack come out 1 (0.3)
Upper gastrointestinal bleed 1 (0.3)
Urinary tract infection, peritonitis 1 (0.3)
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encapsulation rather than incorporation of the biologic prosthesis.
Such studies raise criticism concerning crosslinking but, as our
study suggests, not all crosslinked biologic materials report the
same success rates. In a literature review by Smart et al. [15],
Permacol surgical implant had the lowest failure rate and the
longest time to failure, particularly in contaminated ﬁelds. These
results are concordant with ﬁndings from high-quality animal
studies [16,17].
Diaz et al. [18] conducted a retrospective analysis of 240 patients
who had undergone complex ventral hernia (CVH) repair with a
human acellular dermal tissue matrix (Alloderm, LifeCell, NJ,
USA). CVH was deﬁned as a recurrent ventral hernia in a compro-
mised surgical ﬁeld in which a gastrointestinal, biliary, and/or
genitourinary procedure was performed. Only 5.6% of the cases
were clean, 50% of the study group had at least one comorbidity,
and 70% underwent an additional surgical procedure other than
hernia repair. At a mean follow-up of 317 days, hernia recurrence
rate was 17.1%. In their study, co-morbidity did not increase risk of
hernia recurrence, possibly because there were so few clean cases
(n ¼ 13). In our study, comorbidity also did not increase risk in
hernia recurrence within 12 months, even though 93.6% of our
patients had at least one comorbidity, and 72.3% had two or more
comorbidities.
The only other study publishing two-year hernia recurrence
follow-up data is the RICH study [19]. In this 80-patient open
ventral incisional hernia repair trial, the hernia defects were Clean-
contaminated (48.8%), Contaminated (48.8%), or Dirty (2.5%), with
VHWG [8] Grade 3 and Grade 4 in 75% and 25% of patients,Table 8
Recurrence rates by mesh location and surgical techniques e per-protocol analysis
set.
Recurrence rate at 12 months by mesh location, n/N (%) Per protocol
Inlay 2/17 (11.8)
Onlay 7/37 (18.9)
Sublay 5/39 (12.8)
Underlay
P < 0.0001 versus onlay
6/250 (2.4)
Recurrence at 12 months by surgical techniques (%) Per protocol
RiveseStoppa 1/17 (5.9)
Modiﬁed Stoppa 8/197 (4.1)
Component separation 5/89 (5.6)
Stage approach 0/5 (0)
Onlay repair
P ¼ 0.038 versus modiﬁed Stoppa
4/12 (33.3)
Othera 2/25 (8)
A subject can have more than one surgical technique.
a 2 recurrences at 12 months for 1 subject with a repair abdominal wall and 1
subject with an upper midline laparotomy.respectively. In that study, there were 15 (19%) hernia recurrences
by month 12 and 22 (28%) by month 24. However, it should be
noted that the actual patient follow-up was 69 patients at one year
and 60 patients at two years, so the potential incremental hernia
recurrence rate on the missing 11 and 20 patients to follow-up,
respectively, is unknown. Referring to Table 6, if our Permacol
surgical implant retrospective data is converted from a CDC wound
classiﬁcation to the VHWG grading system, there are 131 patients in
Grade 3 and 22 patients in Grade 4. In our study, hernia recurrence
rates for Grade 3 and Grade 4 patients are 3.82% and 4.55%,
respectively, at 12 months. If we take this analysis one step further
and only include Grade 3 and Grade 4 patients that received open
repair of an incisional hernia (to more closely track RICH study
patients), our study patients drop to 76 and 12 patients, respec-
tively, with corresponding one-year recurrence rates of 2.6% and
0%. It should also be noted that, of these 88 total Grade 3 and Grade
4 open incisional hernia repair patients, 16 (18.2%) have a BMI >40
and 9 (10.2%) were on corticoid treatment, two groups that were
excluded from the RICH study. In addition, our median mesh size
range for our Grade 3 and Grade 4 patients is 300 cm2 with a range
of 25e1000, which appears comparable to the RICH mean hernia
defects of 236  158 cm2 with a range of 8e841. These direct
comparisons are theoretical due to the variability of patient char-
acteristics in Grade 3 and Grade 4; however, the hernia recurrence
rates following the use of Permacol surgical implant are low for
these high-risk patients and comparable to Grade 2 patients in our
retrospective study (Table 6), with no statistical difference from
Grade 1 patients, due to the small sample size (n ¼ 15).
Our study population consisted of patients with ventral and
incisional hernias, including complex abdominal wallTable 10
Post-operative wound infections based on CDC wound classiﬁcation.
Post-operative infections
per wound class, N (%)
Class I e clean (N ¼ 190) 15 (7.9)
Class II e clean-contaminated (N ¼ 103) 22 (16.9)
Class III e contaminated (N ¼ 28) 8 (28.6)
Class IV e dirty-infected (N ¼ 22) 7 (31.8)
Total (N ¼ 343) 52 (15.2)
P value (Fischer exact test) <0.0001
Table 11
Sub-group analyses for the 65 patients with seroma as a post-operative
complication.
N (%)a
Type of surgery Laparoscopic (N ¼ 122) 39 (32)
Open (N ¼ 220) 26 (11.8)
Drain placed (N ¼ 176) 25 (14.2)
Implant placement method Inlay (N ¼ 17) 2 (11.8)
Onlay (N ¼ 37) 6 (16.2)
Sublay (N ¼ 39) 4 (10.3)
Underlay (N ¼ 250) 53 (21.2)
Surgical techniques Component separation (N ¼ 89) 8 (9.0)
Modiﬁed Stoppa (N ¼ 197) 46 (23.4)
Onlay repair (N ¼ 12) 1 (8.3)
Other (N ¼ 25) 6b (9.2)
RiveseStoppa (N ¼ 17) 3 (17.7)
Stage approach (N ¼ 5) 2 (40.0)
Type of surgery Elective (N ¼ 315) 62 (19.7)
Emergent (N ¼ 28) 3 (10.7)
Wound graduation Class I e clean (N ¼ 190) 44 (23.2)
Class II e clean-contaminated
(N ¼ 103)
13 (12.6)
Class III e contaminated (N ¼ 28) 6 (21.4)
Class IV e dirty-infected (N ¼ 22) 2 (9.1)
Infection status at surgery Infected mesh (N ¼ 30) 3 (10)
None (N ¼ 294) 62 (21.1)
Wound infection (N ¼ 19) 0 (0)
Fixation methods Nonresorbable sutures (N ¼ 160) 22 (13.8)
Nonresorbable sutures
þ resorbable sutures (N ¼ 1)
1 (100)
Nonresorbable sutures
þ tacks (N ¼ 20)
1 (5)
Slowly resorbable sutures
(PDS, Maxon) (N ¼ 46)
4 (8.7)
Tacks (N ¼ 110) 37 (33.6)
Other (N ¼ 6) 0 (0)
Surface of mesh, cm2 <200 cm2 (N ¼ 154) 34 (22.1)
200e400 cm2 (N ¼ 89) 11 (12.4)
400 cm2 (N ¼ 93) 19 (20.4)
a N ¼ Number of subjects by category; n ¼ number of subjects with seroma;
% ¼ (n/N).
b There are 6 seromas for subjects with other surgical techniques: 1 primary
fascial closure; 2 intraperitoneal sublayer repair; 1 primary midline; 1 revision of
Indiana pouch, ileostomy; 1 pelvic reinforcement.
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population has one of the highest likelihoods of developing a her-
nia recurrence or surgical site infectious complication, according to
both the CDC and the VHWG [8,20]. The former classiﬁes wounds
that involve an existing clinical infection as dirty or infected (seen
in 6.4% of our study population), or contaminated by an open
wound or a break in sterility (seen in 8.2% of our study population).
Even though the CDC wound classiﬁcations help predict surgical
site infection risk, the overall risk for failure (infection and other) is
signiﬁcantly higher when considering systemic conditions. Our
patient population would also be considered high risk based on
other factors, including degree of obesity, number of medical
comorbidities, and number of previous failed hernia operations.
Over 30% of patients were on a minimum of their third surgical
procedure, with 112 (32.7%) patients being treated for hernia
recurrence with an overall patient population mean BMI of over
33 kg/m2. When using the recently published VHWG grading sys-
tem, over 95% of our study population would be classiﬁed as Grade
2 or higher. The recommended prosthetic for this group of patients,
based on this grading system, would include consideration of a
collagen-based product during abdominal wall reconstruction.
Given our overall low recurrence rate, it was not possible to
determine which patient factor(s) may impact failure rates, with
the exception of an inﬂuence of previous hernia surgery on hernia
recurrence within 24 months. However, surgeon factors (e.g., sur-
gical approach, mesh location, and surgical technique) had asigniﬁcant impact on hernia recurrence rates. We recommend
optimizing controllable patient conditions, performing these
complex operations on an elective basis, reducing the bioburden of
the wound, and reapproximating the fascial midline while utilizing
Permacol surgical implant as reinforcement. As seen in our study,
a greater proportion of patients underwent an underlay subfascial,
intraperitoneal placement of Permacol surgical implant (72.9%)
compared to other methods. Midline fascial closurewas obtained in
88% of cases. Overall, surgeons at all sites attempted to avoid
bridging the defect with the prosthetic, as high failure rates have
been reported when using biologic prosthetics as bridgedmaterials
[21,22]. Component separation was used in 26% of patients in order
to achieve this; however, 11% of patients still required defect
bridging with Permacol surgical implant. When primary closure
is not possible and mesh is used as a bridge between the fascial
edges, this is a clear disadvantage, reducing the amount of contact
the biologic has with a vascular tissue bed.
To the best of our knowledge, this report is the largest evalu-
ating complex abdominal wall reconstruction in higher-risk pa-
tients using Permacol surgical implant. This study reﬂects hernia
surgery across multiple centers on two continents and is a realistic
reﬂection of current surgical practices using Permacol surgical
implant. Given its retrospective nature, there was no standardi-
zation in patient selection or surgical technique, and may be seen
as a study limitation. In addition, inherent in the retrospective
nature of multi-center data collection and analysis are subject
drop-off, potentially varying deﬁnitions, and investigator subjec-
tivity at the time of extraction from patient records and entry into
a central electronic database. Patient subjectivity may also have
resulted in understating hernia recurrence rates when interviewed
over the phone, since no further follow-up was required. This may
be viewed as one of the major limitations of our study; however,
relevant variables (including infectious risk and patient comorbid
conditions), immediate post-operative outcomes, and intermedi-
ate recurrence rates were captured. This approach allows one to
assess current practice trends, which are often more representa-
tive than controlled trials. The development of a well-reasoned
treatment algorithm and improved operative techniques will
continue to lead to improved results in this complex patient
population.
5. Conclusions
This multi-center, multi-national study represents the largest
report of Permacol surgical implant use in incisional and ventral
hernia repair procedures. Permacol surgical implant was shown
to be safe and feasible with low rates of post-operative morbidity
even in patients with higher risk of failure. The intermediate-term
clinical recurrence rates based on KaplaneMeier analysis remain
relatively low. Additional long-term follow-up is required to fully
evaluate Permacol surgical implant in repairing incisional and
ventral hernias in high risk patients.
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